title: Low dose of acetylsalicylic acid and oxidative stress-mediated endothelial dysfunction in diabetes: a short-term evaluation.
abstract: Current guidelines suggest the use of low doses of acetylsalicylic acid (ASA) for patients with diabetes mellitus (DM) in primary prevention. However, the evidences demonstrating the beneficial effect of ASA in primary prevention are conflicting. In this pilot study, we evaluated in a group of diabetic patients, in primary prevention, the impact of ASA treatment on oxidative stress and vascular function. We enrolled 22 newly diagnosed diabetic patients, without any previous clinical evidence of cardiovascular disease, to receive, in primary prevention, ASA (100 mg/daily). We tested, in basal condition, after 4 weeks of ASA administration and after 4 weeks of pharmacological washout, the impact of ASA treatment on endothelial function, assessed by a semipletysmographic method, measuring the main oxidative stress parameters related to it. As expected, after 4 weeks of treatment, ASA induced a significant reduction of plasma thromboxane-A2, as a consequence of cyclooxygenase-1 inhibition. By contrast, ASA significantly increased the plasma and urine 8-iso-PGF2α, a well-known prothrombotic molecule, parallel to an increase of plasma NOX2 levels. The enhancement of this oxidative pathway is associated with a significant impairment of endothelial vasodilation, assessed by reactive hyperemia index (RHI). The pharmacological washout reverted all parameters to basal condition. Our findings suggest that ASA utilization for primary prevention in diabetic patients causes a significant increase of oxidative stress burden impairing the vascular function. Present data, if confirmed on a larger population, could permanently discourage the use of the ASA for the primary prevention in patients with DM.
authors.affiliation: Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Campus Universitario di Germaneto, V.le Europa, 88100, Catanzaro, Italy, eli.jo@alice.it.
authors.forename: Eliezer Joseph
authors.initials: EJ
authors.lastname: Tassone
authors.forename: Maria
authors.initials: M
authors.lastname: Perticone
authors.forename: Angela
authors.initials: A
authors.lastname: Sciacqua
authors.forename: Simona Fortunata
authors.initials: SF
authors.lastname: Mafrici
authors.forename: Chiara
authors.initials: C
authors.lastname: Settino
authors.forename: Natalia
authors.initials: N
authors.lastname: Malara
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Mollace
authors.forename: Giorgio
authors.initials: G
authors.lastname: Sesti
authors.forename: Francesco
authors.initials: F
authors.lastname: Perticone
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D010865:Pilot Projects
chemical_list: D001241:Aspirin
references.citation: Cardiovasc Diabetol. 2011 Apr 01;10:25
references.pmid: 21453547
references.citation: J Am Heart Assoc. 2013 Jun 14;2(3):e000198
references.pmid: 23770972
references.citation: Clin Chim Acta. 2014 Feb 15;429:76-8
references.pmid: 24316050
references.citation: Int J Clin Pract. 2014 Feb;68(2):271-7
references.pmid: 24372992
references.citation: JAMA. 2002 May 15;287(19):2570-81
references.pmid: 12020339
references.citation: JAMA. 2008 Nov 12;300(18):2134-41
references.pmid: 18997198
references.citation: N Engl J Med. 1998 Jul 23;339(4):229-34
references.pmid: 9673301
references.citation: Liver Int. 2011 Nov;31(10):1533-40
references.pmid: 22093328
references.citation: Circulation. 2001 Jul 10;104(2):191-6
references.pmid: 11447085
references.citation: Diabetes. 2001 Jan;50(1):159-65
references.pmid: 11147782
references.citation: JAMA. 2006 Jan 18;295(3):306-13
references.pmid: 16418466
references.citation: Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
references.pmid: 23264422
references.citation: Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):423-34
references.pmid: 21071703
references.citation: J Physiol. 2007 Aug 15;583(Pt 1):9-24
references.pmid: 17584843
references.citation: Diabetes Care. 2011 Jan;34 Suppl 1:S62-9
references.pmid: 21193628
references.citation: J Thromb Haemost. 2004 Aug;2(8):1282-91
references.pmid: 15304032
references.citation: J Thromb Haemost. 2014 Feb;12(2):126-37
references.pmid: 24298905
references.citation: Circulation. 2012 Jul 3;126(1):92-103
references.pmid: 22615342
references.citation: Diabetes. 2012 Jun;61(6):1626-32
references.pmid: 22427378
references.citation: Diabetes. 2008 Jan;57(1):167-71
references.pmid: 17928395
references.citation: Atherosclerosis. 2011 Dec;219(2):463-7
references.pmid: 21937042
references.citation: Thromb Res. 2012 Nov;130(5):746-52
references.pmid: 22959706
references.citation: BMJ. 2002 Jan 12;324(7329):71-86
references.pmid: 11786451
references.citation: BMJ. 2009 Nov 06;339:b4531
references.pmid: 19897665
references.citation: Intern Emerg Med. 2011 Jun;6(3):203-12
references.pmid: 20734162
references.citation: Am J Cardiol. 1991 Sep 3;68(7):11B-15B
references.pmid: 1892057